Start Your Search
P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 948)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
P1.16-09 - Surgical Result of Pathologic Stage III a Non Small Cell Lung Cancer: Have We Improved? (ID 12078)
16:45 - 18:00 | Presenting Author(s): Ching-Yang Wu
Non small cell lung cancer was the leading cause of cancer death worldwide. five-year survival of pathologic stage IIIa still remain poor and the management remain controversial. Many new medicines and surgical techniques were utilized as treatment for pathologic stage IIIIa patient. The aim of study was tried to analyzed the survival impact of these treatment modalities and the stage migration effect during new TNM staging classification system.a9ded1e5ce5d75814730bb4caaf49419 Method
From Jan 2005 to Jun 2014, there were 166 pathologic stage IIIa patients were enrolled into study. All patients were follow up till 2016/7. Patients were divided into two groups since year 2010 because of difference of surgical technique switch. Medical records were reviewed retrospectively and survival status were analyzed.
From January 2005 to May 2014, 166 patients who had received tumor resection and were confirmed as pathologic stage IIIa by 7th AJCC stage classification system were included for further analysis. The 5-year disease free and overall survival rates were 24.9% and 38.2%, respectively. Patients who received neoadjuvant therapy showed inferior disease free survival compared with those without neoadjuvant therapy. ( p< 0.0001). Patients who presented as adenocarcinoma and received tumor resection showed better overall survival than non-adenocarcinoma patients. (p=0.0011) Because the operation method was shifted to video-assisted thoracoscopic surgery in the year 2010, we analyzed survival status separately before and after 2010. In addition, we found that patients who received tumor resection and were conformed as pathologic stage IIIa adenocarcinoma has had better overall survival than other subgroups. (p =0.0005) 28 patients who were identified stage migration had worse disease-free and overall survival.
Disease free survival of pathologic stage IIIa patients remain unchanged but overall survival had much improvement. Patients who presented with adenocarcinoma who received tumor resection during 2010 to 2014 has better survival. This may be related to medical improvement but further investigation was warranted. Stage migration and worse disease and overall survival for those presented as 3b in new stage classification were identified. Different treatment strategy was needed for these patients who were identified stage migration.6f8b794f3246b0c1e1780bb4d4d5dc53